Skip to main content
SpringerLink
Log in

Neoadjuvant Hormonal Therapy in Breast Cancer

  • Chapter
  • First Online:
Breast Disease

  • 1638 Accesses

Abstract

The various types of ER-positive and HER-2-negative breast cancers have different treatment modalities. There are two options for the treatment of locally advanced breast cancer: chemotherapy or hormonal therapy. Chemotherapy can be particularly toxic for elderly postmenopausal patients, and neoadjuvant hormonal therapy (NHT) is an alternative for patients with hormone receptor-positive, locally advanced, postmenopausal breast cancer. This treatment is also highly beneficial for patients with comorbidities and can comprise tamoxifen and steroidal or nonsteroidal aromatase inhibitors (AIs). The best activities in clinical trials are observed with AIs. NHT produces good response rates (RRs) as well as adequate downstaging of tumor size such that breast-conserving surgery (BCS) may become an option. The optimal duration of such treatments should not be less than 4 months and may be continued for as long as 8 months.

 There are no studies showing benefits of neoadjuvant endocrine therapy in premenopausal patients.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 219.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Fisher B, Redmond C, Fisher ER, Bauer M, Wolmark N, Wickerham DL, et al. Ten-year results of a randomized clinical trial comparing radical mastectomy and total mastectomy with or without radiation. N Engl J Med. 1985;312:674–81.

    Article  CAS  PubMed  Google Scholar 

  2. Silliman RA. What constitutes optimal care for older women with breast cancer? J Clin Oncol. 2003;21:3554–6.

    Article  PubMed  Google Scholar 

  3. Krainick-Strobel UE, Lichtenegger W, Wallwiener D, Tulusan AH, Jänicke F, Bastert G, et al. Neoadjuvant letrozole in postmenopausal estrogen and/or progesterone receptor positive breast cancer: a phase IIb/III trial to investigate optimal duration of preoperative endocrine therapy. BMC Cancer. 2008;26(8):62.

    Article  Google Scholar 

  4. Mustacchi G, Milani S, Pluchinotta A, De Matteis A, Rubagotti A, Perrota A, et al. Tamoxifen or surgery plus tamoxifen as primary treatment for elderly patients with operable breast cancer: the G.R.E.T.A. Trial. Group for research on endocrine therapy in the elderly. Anticancer Res. 1994;14:2197–200.

    CAS  PubMed  Google Scholar 

  5. Buzdar A, Howell A. Advances in aromatase inhibition: clinical efficacy and tolerability in the treatment of breast cancer. Clin Cancer Res. 2001;7:2620–35.

    CAS  PubMed  Google Scholar 

  6. Goldhirsh A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thürlimann B, et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer. Ann Oncol. 2013;24(9):2206–23.

    Article  Google Scholar 

  7. Powles TJ, Hickish TF, Makris A, Ashley SE, O'Brien ME, Tidy VA, et al. Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer. J Clin Oncol. 1995;13(3):547–52.

    CAS  PubMed  Google Scholar 

  8. Charehbili A, Fontein DB, Kroep JR, Liefers GJ, Mieog JS, Nortier JW, et al. Neoadjuvant hormonal therapy for endocrine sensitive breast cancer: a systematic review. Cancer Treat Rev. 2014;40(1):86–92.

    Article  CAS  PubMed  Google Scholar 

  9. Horobin JM, Preece PE, Dewar JA, Wood RA, Cuschieri A. Long-term follow-up of elderly patients with locoregional breast cancer treated with tamoxifen only. Br J Surg. 1991;78(2):213–7.

    Article  CAS  PubMed  Google Scholar 

  10. Dixon JM, Love CD, Bellamy CO, Cameron DA, Leonard RC, Smith H, et al. Letrozole as primary medical therapy for locally advanced and large operable breast cancer. Breast Cancer Res Treat. 2001;66(3):191–9.

    Article  CAS  PubMed  Google Scholar 

  11. Dixon JM, Anderson TJ, Miller WR. Neoadjuvant endocrine therapy of breast cancer: a surgical perspective. Eur J Cancer. 2002;38(17):2214–21.

    Article  CAS  PubMed  Google Scholar 

  12. Mauriac L, Debled M, Durand M, Floquet A, Boulanger V, Dagada C, et al. Neoadjuvant tamoxifen for hormone-sensitive non-metastatic breast carcinomas in early postmenopausal women. Ann Oncol. 2002;13(2):293–8.

    Article  CAS  PubMed  Google Scholar 

  13. Tubiana-Hulin M, Becette V, Bieche I, Mauriac L, Romieu G, Bibeau F, et al. Exemestane as neoadjuvant hormonotherapy for locally advanced breast cancer: results of a phase II trial. Anticancer Res. 2007;27(4C):2689–96.

    CAS  PubMed  Google Scholar 

  14. Eiermann W, Paepke S, Appfelstaedt J, Llombart-Cussac A, Eremin J, Vinholes J, et al. Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double blind multicenter study. Ann Oncol. 2001;2(11):1527–32.

    Article  Google Scholar 

  15. Smith IE, Dowsett M, Ebbs SR, Dixon JM, Skene A, Blohmer JU, et al. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the immediate preoperative anastrozole, tamoxifen, or combined with tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol. 2005;23(22):5108–16.

    Article  CAS  PubMed  Google Scholar 

  16. Cataliotti L, Buzdar AU, Noguchi S, Bines J, Takatsuka Y, Petrakova K, et al. Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the pre-operative “Arimidex” Compared to Tamoxifen (PROACT) trial. Cancer. 2006;106(10):2095–103.

    Article  CAS  PubMed  Google Scholar 

  17. Murray J, Young OE, Renshaw L, White S, Williams L, Evans DB, et al. A randomised study of the effects of letrozole and anastrozole on oestrogen receptor positive breast cancers in postmenopausal women. Breast Cancer Res Treat. 2009;114(3):495–501.

    Article  CAS  PubMed  Google Scholar 

  18. Hille U, Soergel P, Langer F, Schippert C, Makowski L, Hillemanns P. Aromatase inhibitors as solely treatment in postmenopausal breast cancer patients. Breast J. 2012;18(2):145–50.

    Article  CAS  PubMed  Google Scholar 

  19. Dixon JM, Renshaw L, Dixon J, Thomas J. Invasive lobular carcinoma: response to neoadjuvant letrozole therapy. Breast Cancer Res Treat. 2011;130(3):871–7.

    Article  CAS  PubMed  Google Scholar 

  20. Olson Jr JA, Budd GT, Carey LA, Harris LA, Esserman LJ, Fleming GF, et al. Improved surgical outcomes for breast cancer patients receiving neoadjuvant aromatase inhibitor therapy: results from a multicenter phase II trial. J Am Coll Surg. 2009;208(5):906–14.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Gazet JC, Ford HT, Gray R, McConkey C, Sutcliffe R, Quilliam J, Makinde V, et al. Estrogen-receptor-directed neoadjuvant therapy for breast cancer: results of a randomised trial using formestane and methotrexate, mitozantrone and mitomycin C (MMM) chemotherapy. Ann Oncol. 2001;12(5):685–91.

    Article  CAS  PubMed  Google Scholar 

  22. Torrisi R, Bagnardi V, Pruneri G, Ghisini R, Bottiglieri L, Magni E, et al. Antitumour and biological effects of letrozole and GnRH analogue as primary therapy in premenopausal women with ER and PgR positive locally advanced operable breast cancer. Br J Cancer. 2007;97(6):802–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Masuda N, Sagara Y, Kinoshita T, Iwata H, Nakamura S, Yanagita Y, et al. Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial. Lancet Oncol. 2012;13(4):345–52.

    Article  CAS  PubMed  Google Scholar 

  24. Ellis MJ, Suman VJ, Hoog J, Lin L, Snider J, Prat A, et al. Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2–3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype – ACOSOG Z1031. J Clin Oncol. 2011;29(17):2342–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Semiglazov VF, Semiglazov VV, Dashyan GA, Ziltsova EK, Ivanov VG, Bozhok AA, et al. Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer. Cancer. 2007;110(2):244–54.

    Article  CAS  PubMed  Google Scholar 

  26. Alba E, Calvo L, Albanell J, De la Haba JR, Arcusa Lanza A, Chacon JI, et al. Chemotherapy (CT) and hormonotherapy (HT) as neoadjuvant treatment in luminal breast cancer patients: results from the GEICAM/2006-03, a multicenter, randomized, phase-II study. Ann Oncol. 2012;23(12):3069–74.

    Article  CAS  PubMed  Google Scholar 

  27. Colleoni M, Montagna E. Neoadjuvant therapy for ER-positive breast cancers. Ann Oncol. 2012;23 Suppl 10:x243–8.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Oncology, Koc University Medical Faculty, Topkapi/İstanbul, Turkey

    Nil Molinas Mandel MD & Fatih Selcukbiricik MD

  2. Department of Medical Oncology, VKV American Hospital, Güzelbahce Sokak, Nısantas, SISLI, Istanbul, Turkey

    Nil Molinas Mandel MD

Authors
  1. Nil Molinas Mandel MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Fatih Selcukbiricik MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nil Molinas Mandel MD .

Editor information

Editors and Affiliations

  1. Inst of Oncology,Ist Tıp Fak, Istanbul University, Istanbul, Turkey

    Adnan Aydiner

  2. General Surgery, Istanbul Univ Istanbul Fac of Med, Istanbul, Turkey

    Abdullah İgci

  3. Breast Surgery,, Magee-Womens Hospital, Pittsburg, USA

    Atilla Soran

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Mandel, N.M., Selcukbiricik, F. (2016). Neoadjuvant Hormonal Therapy in Breast Cancer. In: Aydiner, A., İgci, A., Soran, A. (eds) Breast Disease. Springer, Cham. https://doi.org/10.1007/978-3-319-26012-9_14

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-26012-9_14

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-26010-5

  • Online ISBN: 978-3-319-26012-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation